AR043006A1 - Proceso para preparar ribonucleosidos ramificados - Google Patents
Proceso para preparar ribonucleosidos ramificadosInfo
- Publication number
- AR043006A1 AR043006A1 ARP040100318A ARP040100318A AR043006A1 AR 043006 A1 AR043006 A1 AR 043006A1 AR P040100318 A ARP040100318 A AR P040100318A AR P040100318 A ARP040100318 A AR P040100318A AR 043006 A1 AR043006 A1 AR 043006A1
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- structural formula
- pyrimidine
- pyrrolo
- preparation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/048—Pyridine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/14—Pyrrolo-pyrimidine radicals
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Abstract
Proceso para la preparación de ribonucleósidos de cadena ramificada inhibidores de la polimerasa HCV para el tratamiento de la infección HCV. Reivindicación 1: Un proceso para la preparación de un compuesto con fórmula estructural (1) donde R1 es C1-6 alquil y B es una purina o nucleobase pirimidina seleccionada entre el grupo consistente en citosina, uracilo, timina,, hipoxantina, adenina, guanina, 7-deazaguanina, 7-deazaadenina, 7-deaza-2,6-diaminopurina, y 7-deazahipoxantina; que comprende los pasos de (a) producir un compuesto de fórmula estructural (4) donde B´ es opcionalmente B protegido, mediante el contacto con un compuesto de fórmula estructural (2) donde PG es un grupo protector hidroxilo, con un nucleofilo B´ en un solvente orgánico adecuado; y (b) eliminado los grupos protectores hidroxilo PG y opcionalmente los grupos protectores en B´ Reivindicación 14: 4-amino-7-(2-C-metil-b-D-ribofuranosil)-7H-pirrolo[2,3-d]pirimidina en la forma de un solvato tolueno cristalino. Reivindicación 15: Un compuesto el cual es 4-ftalimido-7H-pirrolo[2,3-d]pirimidina.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US44693503P | 2003-02-12 | 2003-02-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR043006A1 true AR043006A1 (es) | 2005-07-13 |
Family
ID=32869576
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP040100318A AR043006A1 (es) | 2003-02-12 | 2004-02-02 | Proceso para preparar ribonucleosidos ramificados |
Country Status (7)
Country | Link |
---|---|
US (1) | US7339054B2 (es) |
EP (1) | EP1594882B1 (es) |
AR (1) | AR043006A1 (es) |
AT (1) | ATE435231T1 (es) |
DE (1) | DE602004021774D1 (es) |
TW (1) | TWI320787B (es) |
WO (1) | WO2004072090A1 (es) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
EA200601591A1 (ru) | 2000-05-26 | 2007-02-27 | Айденикс (Кайман) Лимитед | Применение рибонуклеозидных соединений для лечения флавивирусных и пестивирусных инфекций |
WO2004009020A2 (en) | 2002-07-24 | 2004-01-29 | Merck & Co., Inc. | Pyrrolopyrimidine thionucleoside analogs as antivirals |
EP1576138B1 (en) | 2002-11-15 | 2017-02-01 | Idenix Pharmaceuticals LLC. | 2'-methyl nucleosides in combination with interferon and flaviviridae mutation |
AR043006A1 (es) * | 2003-02-12 | 2005-07-13 | Merck & Co Inc | Proceso para preparar ribonucleosidos ramificados |
US20080261913A1 (en) | 2006-12-28 | 2008-10-23 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of liver disorders |
AU2010226466A1 (en) * | 2009-03-20 | 2011-10-20 | Alios Biopharma, Inc. | Substituted nucleoside and nucleotide analogs |
EP2552203B1 (en) | 2010-04-01 | 2017-03-22 | Idenix Pharmaceuticals LLC. | Compounds and pharmaceutical compositions for the treatment of viral infections |
CA2810928A1 (en) | 2010-09-22 | 2012-03-29 | Alios Biopharma, Inc. | Substituted nucleotide analogs |
EP2691409B1 (en) | 2011-03-31 | 2018-02-21 | Idenix Pharmaceuticals LLC. | Compounds and pharmaceutical compositions for the treatment of viral infections |
EP2755983B1 (en) | 2011-09-12 | 2017-03-15 | Idenix Pharmaceuticals LLC. | Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections |
US8507460B2 (en) | 2011-10-14 | 2013-08-13 | Idenix Pharmaceuticals, Inc. | Substituted 3′,5′-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections |
CA2860234A1 (en) | 2011-12-22 | 2013-06-27 | Alios Biopharma, Inc. | Substituted phosphorothioate nucleotide analogs |
CN104321333A (zh) | 2012-03-21 | 2015-01-28 | 沃泰克斯药物股份有限公司 | 硫代氨基磷酸酯核苷酸前药的固体形式 |
WO2013142157A1 (en) | 2012-03-22 | 2013-09-26 | Alios Biopharma, Inc. | Pharmaceutical combinations comprising a thionucleotide analog |
AU2013266393B2 (en) | 2012-05-22 | 2017-09-28 | Idenix Pharmaceuticals Llc | D-amino acid compounds for liver disease |
US9296778B2 (en) | 2012-05-22 | 2016-03-29 | Idenix Pharmaceuticals, Inc. | 3′,5′-cyclic phosphate prodrugs for HCV infection |
EP2852604B1 (en) | 2012-05-22 | 2017-04-12 | Idenix Pharmaceuticals LLC | 3',5'-cyclic phosphoramidate prodrugs for hcv infection |
EA027929B1 (ru) | 2012-05-25 | 2017-09-29 | Янссен Сайенсиз Айрлэнд Юси | Нуклеозиды на основе урацила и спирооксетана |
WO2014052638A1 (en) | 2012-09-27 | 2014-04-03 | Idenix Pharmaceuticals, Inc. | Esters and malonates of sate prodrugs |
ES2674980T3 (es) | 2012-10-08 | 2018-07-05 | Idenix Pharmaceuticals Llc | Análogos de 2'-cloro nucleósidos para infección por VHC |
US10723754B2 (en) | 2012-10-22 | 2020-07-28 | Idenix Pharmaceuticals Llc | 2′,4′-bridged nucleosides for HCV infection |
EP2935304A1 (en) | 2012-12-19 | 2015-10-28 | IDENIX Pharmaceuticals, Inc. | 4'-fluoro nucleosides for the treatment of hcv |
US9309275B2 (en) | 2013-03-04 | 2016-04-12 | Idenix Pharmaceuticals Llc | 3′-deoxy nucleosides for the treatment of HCV |
US9339541B2 (en) | 2013-03-04 | 2016-05-17 | Merck Sharp & Dohme Corp. | Thiophosphate nucleosides for the treatment of HCV |
EP2970357A1 (en) | 2013-03-13 | 2016-01-20 | IDENIX Pharmaceuticals, Inc. | Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv |
WO2014165542A1 (en) | 2013-04-01 | 2014-10-09 | Idenix Pharmaceuticals, Inc. | 2',4'-fluoro nucleosides for the treatment of hcv |
BR112015025716A2 (pt) | 2013-04-12 | 2017-07-18 | Achillion Pharmaceuticals Inc | pró-fármacos de nucleosídeo submetidos a deutério úteis para o tratamento de hcv |
US10005779B2 (en) | 2013-06-05 | 2018-06-26 | Idenix Pharmaceuticals Llc | 1′,4′-thio nucleosides for the treatment of HCV |
EP3027636B1 (en) | 2013-08-01 | 2022-01-05 | Idenix Pharmaceuticals LLC | D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease |
WO2015161137A1 (en) | 2014-04-16 | 2015-10-22 | Idenix Pharmaceuticals, Inc. | 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv |
UA124966C2 (uk) | 2015-03-06 | 2021-12-22 | Атеа Фармасеутікалс, Інк. | <font face="Symbol">b</font>-D-2'-ДЕЗОКСИ-2'-<font face="Symbol">a</font>-ФТОР-2'-<font face="Symbol">b</font>-C-ЗАМІЩЕНІ-2-МОДИФІКОВАНІ-N<sup>6</sup>-ЗАМІЩЕНІ ПУРИНОВІ НУКЛЕОТИДИ ДЛЯ ЛІКУВАННЯ ВИКЛИКАНИХ HCV ЗАХВОРЮВАНЬ |
LU100724B1 (en) | 2016-07-14 | 2018-07-31 | Atea Pharmaceuticals Inc | Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection |
EP3865136A1 (en) | 2016-09-07 | 2021-08-18 | ATEA Pharmaceuticals, Inc. | 2'-substituted-n6-substituted purine nucleotides for corona virus treatment |
KR20230151050A (ko) | 2017-02-01 | 2023-10-31 | 아테아 파마슈티컬즈, 인크. | C형 간염 바이러스를 치료하기 위한 뉴클레오티드 헤미-술페이트 염 |
TW202012001A (zh) | 2018-04-10 | 2020-04-01 | 美商亞堤製藥公司 | C型肝炎病毒(hcv)感染硬化之患者的治療 |
US10874687B1 (en) | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
US20220251088A1 (en) * | 2020-12-10 | 2022-08-11 | Prelude Therapeutics, Incorporated | Processes for Making PRMT5 Inhibitors |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3037980A (en) | 1955-08-18 | 1962-06-05 | Burroughs Wellcome Co | Pyrrolopyrimidine vasodilators and method of making them |
US3480613A (en) | 1967-07-03 | 1969-11-25 | Merck & Co Inc | 2-c or 3-c-alkylribofuranosyl - 1-substituted compounds and the nucleosides thereof |
MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
EA200601591A1 (ru) | 2000-05-26 | 2007-02-27 | Айденикс (Кайман) Лимитед | Применение рибонуклеозидных соединений для лечения флавивирусных и пестивирусных инфекций |
BR0114837A (pt) | 2000-10-18 | 2006-05-09 | Pharmasset Ltd | nucleosìdeos modificados para tratamento de infecções viróticas e proliferação celular anormal |
WO2002057287A2 (en) | 2001-01-22 | 2002-07-25 | Merck & Co., Inc. | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
AR043006A1 (es) * | 2003-02-12 | 2005-07-13 | Merck & Co Inc | Proceso para preparar ribonucleosidos ramificados |
CA2584367A1 (en) * | 2004-10-21 | 2006-06-22 | Merck & Co., Inc. | Fluorinated pyrrolo[2,3-d]pyrimidine nucleosides for the treatment of rna-dependent rna viral infection |
-
2004
- 2004-02-02 AR ARP040100318A patent/AR043006A1/es unknown
- 2004-02-06 WO PCT/US2004/003469 patent/WO2004072090A1/en active Application Filing
- 2004-02-06 EP EP04709000A patent/EP1594882B1/en not_active Expired - Lifetime
- 2004-02-06 AT AT04709000T patent/ATE435231T1/de not_active IP Right Cessation
- 2004-02-06 DE DE602004021774T patent/DE602004021774D1/de not_active Expired - Lifetime
- 2004-02-06 US US10/544,575 patent/US7339054B2/en not_active Expired - Fee Related
- 2004-02-11 TW TW093103187A patent/TWI320787B/zh not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
US7339054B2 (en) | 2008-03-04 |
TW200508244A (en) | 2005-03-01 |
DE602004021774D1 (de) | 2009-08-13 |
WO2004072090A1 (en) | 2004-08-26 |
TWI320787B (en) | 2010-02-21 |
EP1594882B1 (en) | 2009-07-01 |
US20070037771A1 (en) | 2007-02-15 |
ATE435231T1 (de) | 2009-07-15 |
EP1594882A1 (en) | 2005-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR043006A1 (es) | Proceso para preparar ribonucleosidos ramificados | |
ES2402597T3 (es) | Nucleósidos modificados para el tratamiento de infecciones víricas y proliferación celular anormal | |
ES2620131T3 (es) | Nucleótidos marcados | |
PE20130807A1 (es) | Metodos para la preparacion de profarmacos de fosforamidato diastereomericamente puros | |
AU2002228749A1 (en) | Modified nucleosides for treatment of viral infections and abnormal cellular proliferation | |
PE20060607A1 (es) | Derivados de indol tetraciclicos como agentes antivirales | |
AR082066A2 (es) | Metodo y uso de analogos de nucleosidos fluorados modificados | |
WO2002069903A3 (en) | Nucleosides, preparation thereof and use as inhibitors of rna viral polymerases | |
JP2010528987A5 (es) | ||
JP2001525411A5 (es) | ||
CN102918052A (zh) | 硫代磷酸核糖核苷的制造方法 | |
IL209917A (en) | Nucleotides and Nucleosides and Their Methods for Use in DNA Flooring | |
PL164785B1 (en) | Method of obtaining novel substituted -1,3-oxathiolanes | |
RU96118248A (ru) | 3'-замещенное производное нуклеозида | |
IE883406L (en) | 2',3'-Dideoxy-2'-fluoronucleosides | |
WO1991019713A1 (en) | Pyrimidine nucleoside derivative | |
FI90876C (fi) | Menetelmä uusien terapeuttisesti käyttökelpoisten aristeromysiini/adenosiinijohdannaisten valmistamiseksi | |
MY130927A (en) | Anhydrous crystalline 1-(4(s)-azido-2(s), 3(r)-dihydroxy-4-(hydroxymethyl)-1(r)-cyclopentyl)cytosine hemisulfate as useful as an antiviral agent | |
Shin et al. | Identification of 6′-β-fluoro-homoaristeromycin as a potent inhibitor of chikungunya virus replication | |
IE67543B1 (en) | Novel acetylenic cyano and allenic aristeromycin/adenosine derivatives | |
CA2506797A1 (en) | Detectable labeled nucleoside analogs and methods of use thereof | |
DK1165560T3 (da) | 2-Hydroxymethylcyclopropylidenmethylpuriner som antivirale midler | |
ATE496056T1 (de) | Pyrimidinverbindungen mit phosphonatgruppen als antivirale nucleotidanaloga | |
AR051338A1 (es) | Procedimiento para preparar compuestos de purina | |
EP0936911B1 (en) | Adenosine deaminase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |